797PD - LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO)

N Matsubara,K.N Chi,M Ozguroglu,A Rodriguez Antolin,S Feyerabend,L Fein,B.Y Alekseev,G Sulur,A Protheroe,S Li,S.D Mundle,P De Porre,N Tran,K Fazazi

doi:10.1093/annonc/mdy284.006

797PD - LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO)

N Matsubara, K.N Chi + Show 12 more

Open Access

https://doi.org/10.1093/annonc/mdy284.006

Copy DOI

Journal: Annals of Oncology	Publication Date: Oct 1, 2018
Citations: 3	License type: publisher-specific-oa

Affiliation: Institut Gustave Roussy, Janssen (United States), Instituto de Oncología de Rosario, University of Oxford, University of Tübingen, National Cancer Center Hospital East

#Abiraterone Acetate And Prednisone #Metastatic Hormone-sensitive Prostate Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

797PD - LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO)

Full Text